Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Personalis, Inc. - Common Stock (NQ:PSNL)

8.520 -0.100 (-1.16%)
Streaming Delayed Price Updated: 10:08 AM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 257,959
Open 8.540
Bid (Size) 8.470 (100)
Ask (Size) 8.600 (200)
Prev. Close 8.620
Today's Range 8.260 - 8.820
52wk Range 2.826 - 11.50
Shares Outstanding 48,518,901
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top movers in Tuesday's pre-market session ↗
Via Chartmill
News headline image
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test ↗
Medicare will reimburse the company’s NeXT Personal molecular residual disease (MRD) test when used to monitor patients with early to mid-stage non-small cell lung cancer (NSCLC). 
Via Stocktwits
Topics Artificial Intelligence

Performance

YTD
+8.5%
+8.5%
1 Month
-0.6%
-0.6%
3 Month
+0.9%
+0.9%
6 Month
+86.4%
+86.4%
1 Year
+70.1%
+70.1%

More News

Read More
News headline image
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance
From Personalis, Inc.
Via Business Wire
News headline image
AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit ↗
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
AIGH Capital Dumps 1.1 Million MaxLinear (MXL) Shares ↗
Via The Motley Fool
News headline image
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors
From Personalis, Inc.
Via Business Wire
News headline image
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Personalis, Inc.
Via Business Wire
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Big Stocks Moving Higher On Monday ↗
Via Benzinga
News headline image
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer
From Personalis, Inc.
Via Business Wire
News headline image
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Personalis Reports Third Quarter 2025 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Announce Third Quarter 2025 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
News headline image
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate in Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga

Frequently Asked Questions

Is Personalis, Inc. - Common Stock publicly traded?
Yes, Personalis, Inc. - Common Stock is publicly traded.
What exchange does Personalis, Inc. - Common Stock trade on?
Personalis, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Personalis, Inc. - Common Stock?
The ticker symbol for Personalis, Inc. - Common Stock is PSNL on the Nasdaq Stock Market
What is the current price of Personalis, Inc. - Common Stock?
The current price of Personalis, Inc. - Common Stock is 8.520
When was Personalis, Inc. - Common Stock last traded?
The last trade of Personalis, Inc. - Common Stock was at 02/11/26 10:08 AM ET
What is the market capitalization of Personalis, Inc. - Common Stock?
The market capitalization of Personalis, Inc. - Common Stock is 413.38M
How many shares of Personalis, Inc. - Common Stock are outstanding?
Personalis, Inc. - Common Stock has 413M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.